Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Severe COVID-19 ARDS
NCT04416139Phase 2Unknown
- Sponsor
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of mesenchymal stem cells in COVID-19 pneumonia, acute respiratory distress syndrome (ARDS), sponsored by Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
COVID-19 pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04416139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04416139.